Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
ZOLEDRONINEZUUR 1-WATER SAMENSTELLING overeenkomend met ; ZOLEDRONINEZUUR 0-WATER
Stada Arzneimittel AG Stadastrasse 2-18 61118 BAD VILBEL (DUITSLAND)
M05BA08
Zoledronic acid 1-WATER COMPOSITION corresponding to ; zoledronic acid 0-WATER
Oplossing voor infusie
MANNITOL (D-) (E 421) ; STIKSTOF (HEAD SPACE) (E 941) ; TRINATRIUMCITRAAT 2-WATER (E 331) ; WATER VOOR INJECTIE,
Intraveneus gebruik
Zoledronic Acid
Hulpstoffen: MANNITOL (D-) (E 421); STIKSTOF (HEAD SPACE) (E 941); TRINATRIUMCITRAAT 2-WATER (E 331); WATER VOOR INJECTIE;
2017-03-29
PACKAGE LEAFLET: INFORMATION FOR THE USER ZOLESTAD 5 MG/100 ML, OPLOSSING VOOR INFUSIE Zoledronic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE, BECAUSE IT CONTAINS INPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. _ _ WHAT IS IN THIS LEAFLET 1. What Zolestad is and what it is used for 2. What you need to know before you are given Zolestad 3. How Zolestad is given 4. Possible side effects 5. How to store Zolestad 6. Contents of the pack and other information 1. WHAT ZOLESTAD IS AND WHAT IT IS USED FOR Zolestad contains the active substance zoledronic acid. It belongs to a group of medicines called bisphosphonates and is used to treat post-menopausal women and adult men with osteoporosis or osteoporosis caused by treatment with corticosteroids used to treat inflammation and Paget’s disease of the bone in adults. OSTEOPOROSIS Osteoporosis is a disease that involves the thinning and weakening of the bones and is common in women after the menopause, but can also occur in men. At the menopause, a woman’s ovaries stop producing the female hormone oestrogen, which helps keep bones healthy. Following the menopause bone loss occurs, bones become weaker and break more easily. Osteoporosis could also occur in men and women because of the long term use of steroids, which can affect the strength of bones. Many patients with osteoporosis have no symptoms but they are still at risk of breaking bones because osteoporosis has made their bones weaker. Decreased circulating levels of sex hormones, mainly oestrogens converted from androgens, also play a role in the more gradual bone loss observed in men. In both women and men, Zolestad strengthens the bone and therefore makes it less likely to break. Zolestad is also used in patients who ha Lees het volledige document
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Zolestad 5 mg/100 ml, oplossing voor infusie 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial with 100 ml of solution contains 5 mg zoledronic acid (as monohydrate). Each ml of the solution contains 0.05 mg zoledronic acid (as monohydrate). Excipient(s) with known effect This medicinal product contains less than 1 mmol sodium (23 mg) per 100 ml of Zolestad, i.e. essentially ‘sodium free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion Clear, colourless, sterile solution. pH: 5.50-7.00 Osmolality (Osmol / kg): 0.23-0.33 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of osteoporosis • in post-menopausal women • in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy • in post-menopausal women • in adult men at increased risk of fracture. Treatment of Paget’s disease of the bone in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Patients must be appropriately hydrated prior to administration of Zolestad. This is especially important for the elderly (≥65 years) and for patients receiving diuretic therapy. Adequate calcium and vitamin D intake are recommended in association with Zolestad administration. 2 _Osteoporosis _ For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg Zolestad administered once a year. The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of Zolestad on an individual patient basis, particularly after 5 or more years of use. In patients with a recent low-trauma hip fracture, it is recommended to Lees het volledige document